Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Tirzepatide peptide icon, one bubble per amino acidTirzepatide39 residuesYAEGTFTSDYSIALDKIAQKAFVQWLIAGGPSSGAPPPSEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Tirzepatide

Beginner tier: 2.5 mg, weekly · FDA label

Weight LossFDA Approved
~5 days half-life·Injection

Also known as: LY3298176, Mounjaro, Zepbound

20.9% mean body weight reduction at 72 weeks on the 15 mg dose, counting everyone randomized. Tirzepatide (Mounjaro, Zepbound, CAS 2023788-19-2) is an FDA-approved dual GIP/GLP-1 receptor agonist, the first drug in its class to target both incretin hormones at once. In the SURMOUNT-5 head-to-head trial, it beat semaglutide 2.4 mg by nearly seven percentage points for total weight lost. The black box warning for thyroid C-cell tumors (rodent data, human relevance unknown) stays on the label. Obesity medicine physicians, type 2 diabetes patients, and adults who plateaued on semaglutide are the primary users.

What Is Tirzepatide?

20.2% body weight gone at 72 weeks, and that was the average, not the ceiling. Tirzepatide (LY3298176, CAS 2023788-19-2) is a 39-amino acid acylated lipopeptide sold as Zepbound for obesity and Mounjaro for type 2 diabetes. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously.

The dual receptor mechanism separates tirzepatide from single-target GLP-1 drugs like semaglutide. GIP receptor activation improves fat metabolism and may reduce the nausea burden that limits GLP-1-only treatment. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and boosts insulin secretion. Those two pathways working together produce weight loss and glycemic control that neither achieves alone.

SURMOUNT-1 (n=2,539)[1] showed dose-dependent results at 72 weeks. Its treatment-regimen estimand counts everyone randomized, including people who stopped the drug. On that basis, mean weight loss was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% on placebo. SURMOUNT-5 (n=751)[2] ran a direct comparison; tirzepatide reached 20.2% versus semaglutide's 13.7%. Roughly one in five tirzepatide patients lost 30% or more of their body weight.

The r/Zepbound community (180,000+ members) confirms what the trials found. Appetite suppression starts within days. Most users stabilize at 7.5 to 12.5 mg rather than pushing to the maximum 15 mg dose. Cost and insurance coverage remain the biggest barriers. Weight regain after stopping is well-documented; about two-thirds of lost weight returns within a year of discontinuation.

How Tirzepatide Works

Tirzepatide binds to two separate incretin receptors on the same molecule. At the GIP receptor, its affinity matches native GIP closely. At the GLP-1 receptor, affinity is roughly 18 to 20-fold lower, making it what researchers call an "imbalanced" agonist that leans toward GIP-mediated pathways.

GLP-1 receptor activation does the heavy lifting on appetite. GLP-1 activation suppresses hunger signaling in the hypothalamus, slows gastric emptying so food stays in the stomach longer, and triggers glucose-dependent insulin release from pancreatic beta cells. These effects explain the "food noise" silencing that users describe within days of their first injection.

GIP receptor activation adds a second layer. GIP activation improves insulin sensitivity, increases adiponectin (a fat-tissue hormone linked to metabolic health), and appears to improve beta-cell function over time. The GIP component may also explain why tirzepatide causes less nausea than pure GLP-1 agonists; SURMOUNT-5 recorded a GI discontinuation rate of just 2.7% for tirzepatide versus 5.6% for semaglutide.

The combined effect on body weight exceeds what either pathway produces alone. SURMOUNT-1 data confirmed dose-dependent fat mass reduction, with approximately 75% of total weight loss coming from fat tissue and 25% from lean mass.

Tirzepatide Benefits

  • Tirzepatide benefits span weight loss, glycemic control, cardiovascular risk reduction, and metabolic improvement across multiple organ systems.
  • Tirzepatide achieved 20.9% mean weight loss at the 15 mg dose over 72 weeks in SURMOUNT-1, counting everyone randomized (n=2,539)[1]. Nearly one in three patients on the highest dose lost 25% or more.
  • Head-to-head superiority over semaglutide confirmed. SURMOUNT-5 (n=751)[2] showed 20.2% loss with tirzepatide versus 13.7% with semaglutide 2.4 mg at 72 weeks, with a lower GI dropout rate (2.7% vs 5.6%).
  • A1c reduction of 1.9 to 2.3 percentage points at 40 weeks in the SURPASS-1 and SURPASS-2 trials [3][4]. That puts tirzepatide among the most potent glycemic agents available for type 2 diabetes.
  • SURMOUNT-OSA [5] showed a 55-63% reduction in apnea-hypopnea index scores. FDA approved tirzepatide for moderate-to-severe obstructive sleep apnea with obesity in December 2024.
  • Three-year T2D prevention data from the SURMOUNT-1 follow-up [6]: 94% of prediabetic participants on tirzepatide avoided progression to type 2 diabetes, compared to 40% with lifestyle changes alone.
  • SUMMIT trial [7] showed improvement in heart failure with preserved ejection fraction (HFpEF) symptoms. SYNERGY-NASH [8] demonstrated MASH resolution in a high proportion of patients with metabolic dysfunction-associated steatohepatitis.

Tirzepatide: Science vs Community Consensus

Aligned
Scientific Evidence
Strong
Based on 22 key studies·FDA-approved

FDA-approved dual GIP/GLP-1 agonist with the strongest weight-loss efficacy of any approved drug class.

Dosing studied: 2.5 mg to 15 mg weekly (subcutaneous). Titrate by 2.5 mg increments every 4 weeks minimum.
Read the evidence (key study, limitations)

SURMOUNT-1 demonstrated 20.9% mean body weight reduction at 15 mg over 72 weeks counting everyone randomized, and 22.5% among those who stayed on treatment. SURMOUNT-5 proved superiority over semaglutide 2.4 mg (−20.2% vs −13.7%). SURPASS-CVOT showed non-inferiority (not superiority) to dulaglutide for major cardiovascular events. Additional FDA approvals: obstructive sleep apnea (Dec 2024). SUMMIT (HFpEF) and SYNERGY-NASH (MASH) trials positive.

Key Study

SURMOUNT-1 (NEJM 2022, PMID 35658024): n=2,539 adults with obesity (no T2D), 72 weeks; −15.0% (5mg), −19.5% (10mg), −20.9% (15mg) vs −3.1% placebo, counting everyone randomized; −16.0%, −21.4%, −22.5% vs −2.4% among those who stayed on treatment. SURMOUNT-5 (NEJM 2025, PMID 40353578): n=751, open-label head-to-head, −20.2% tirzepatide vs −13.7% semaglutide 2.4mg at 72 weeks; 19.7% of tirzepatide patients lost ≥30% body weight vs 6.9% semaglutide. GI discontinuation rate lower with tirzepatide (2.7% vs 5.6%).

Limitations

Weight is largely regained after discontinuation: ~two-thirds within 12 months (SURMOUNT extension). Long-term human data beyond 72 weeks is limited outside of the 3-year T2D prevention endpoint. Black box warning for thyroid C-cell tumors remains: human relevance unknown. Approximately 25% of lost weight is lean mass without active resistance training. SURPASS-CVOT met non-inferiority vs dulaglutide but did not meet superiority on primary MACE endpoint (HR 0.92, 95.3% CI 0.83 to 1.01). No head-to-head cardiovascular outcomes data vs semaglutide.

Community Experience
Strong
4.5/5
Based on r/Zepbound (~180k+ members), r/tirzepatide, r/mounjaro. Largest dedicated Zepbound community on Reddit with tens of thousands of individual protocol posts, weekly check-ins, and outcome reports.

Strongest community enthusiasm of any GLP-1. r/Zepbound users consistently report superior appetite suppression and weight loss vs their prior semaglutide experience.

Community dosing: 2.5 mg to 15 mg weekly. Majority stabilize at 7.5–12.5 mg. Many intentionally stay at their lowest effective dose rather than escalating to maximum.
Read the reports (what users report 7, common issues 9)

Primary concerns: cost and insurance denials, GI side effects during escalation, muscle loss, and fear of lifelong dependency. Slow titration (6-8 weeks per step vs FDA's 4 weeks) is the dominant community protocol for GI tolerance.

What users report (7)
  • "Food noise" silencing: appetite suppression often more complete than prior semaglutide experience
  • Consistent 1.5–2.5 lbs/week weight loss at therapeutic doses
  • Better GI tolerability than semaglutide: lower discontinuation rate confirmed by SURMOUNT-5 and community reports
  • Reduced alcohol cravings widely reported (not in label)
  • Blood sugar and energy improvements measurable before significant weight loss
  • Sleep apnea improvement reported within weeks of starting
  • Decreased cravings for high-fat, high-sugar foods
Common issues (9)
  • Nausea and vomiting during dose escalation: can be work-limiting for some users
  • Constipation nearly universal; daily fiber or osmotic laxatives become routine
  • Hair thinning (telogen effluvium from rapid weight loss): typically starts 2-3 months in, self-resolves
  • Muscle loss without deliberate resistance training and high protein
  • Cost and insurance denials: largest source of frustration and dropout
  • Weight regain after stopping is demoralizing and well-documented
  • "Tirzepatide face": facial volume loss with rapid significant weight loss
  • Sulfur burps during escalation phases
  • Fatigue in first 2-4 weeks after each dose increase
Science & Community Aligned

Science and community fully agree on core findings: tirzepatide produces 20%+ weight loss at maximum tolerated doses, GI side effects are the limiting factor during titration, and weight returns when stopped. Community-evolved slow titration (6-8 week steps) is evidence-consistent and not in label. Community preference to stay at lowest effective dose (not always escalating to 15mg) aligns with clinical guidance that the right dose is the lowest achieving therapeutic goals.

Tirzepatide Dosage Guide

FDA LabelZepbound FDA Prescribing Information (2026), NDA 217806 (n=2,539 (SURMOUNT-1))Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner2.5 mg
WeeklyTrack
Moderate5 mg
WeeklyTrack
Aggressive15 mg
WeeklyTrack

Going up in steps? Track the dose ladder

Note:

Tirzepatide comes in pre-filled pens (brand Zepbound/Mounjaro) and compounded vials (very limited availability since March 2025). For compounded vials:

Reconstitution math for a 10 mg vial with 2 mL bacteriostatic water gives you 5 mg/mL. A 2.5 mg dose is 0.5 mL (50 units on an insulin syringe). A 5 mg dose is 1.0 mL (100 units, a full syringe).

For a 15 mg vial with 2 mL BAC water, concentration is 7.5 mg/mL. A 7.5 mg dose is 1.0 mL (100 units). A 10 mg dose runs about 1.33 mL, which exceeds a standard 1 mL syringe; either use a 3 mL syringe or reconstitute with 3 mL instead (giving 5 mg/mL, then 2.0 mL per 10 mg dose).

The thing most beginners miss: 2.5 mg is not a therapeutic dose for weight loss. It's a tolerability test. Don't judge whether tirzepatide "works" until you've been at 5 mg for at least 4 weeks. Evening injections help most people sleep through the nausea window (4 to 8 hours post-dose).

Cycling

No scheduled off period.

Intended for long-term use. Weight regain expected upon discontinuation. Maintenance dosing may be lower than escalation dose.

Calculate your Tirzepatide dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Tirzepatide Protocols by Goal

beginnerFDA Label72 weeks minimum based on pivotal trials; intended for long-term/indefinite use per FDA label
Phase 1: Tolerability
Wk 1–4
2.5 mg · Once weekly · Subcutaneous
Phase 2: Early Therapeutic
Wk 5–8
5 mg · Once weekly · Subcutaneous
Phase 3: Maintenance Option A
Wk 9–12
7.5 mg · Once weekly · Subcutaneous
Phase 4: Maintenance Option B
Wk 13–16
10 mg · Once weekly · Subcutaneous
Phase 5: Maintenance Option C
Wk 17–20
12.5 mg · Once weekly · Subcutaneous

Expected: SURMOUNT-1 at 72 weeks: −15.0% (5mg), −19.5% (10mg), −20.9% (15mg) vs −3.1% on placebo. SURMOUNT-5: −20.2% at maximum tolerated dose vs −13.7% for semaglutide 2.4mg (72 weeks, open-label head-to-head).

Monitor: A1c and fasting glucose at baseline and 3-month intervals (T2D). Renal function if significant GI fluid losses. TSH if symptoms of thyroid disease. Serum lipase only if severe abdominal pain (not routine screen). Lipid panel and blood pressure at 6-month intervals. Weight and waist circumference monthly.

Who Uses Tirzepatide?

Bryan Johnson
Bryan Johnson

Entrepreneur & Longevity Pioneer

Raised RHR +3bpm, lowered HRV -7pts, sleep quality -10%. Halted after 3 weeks.

500 mcg weekly · subcutaneous
Bryan JohnsonHunter Williams
Bryan Johnson, Hunter Williams
have published Tirzepatide protocols with dosing

How to Inject Tirzepatide

  1. 1
    Step 1

    Gather supplies: tirzepatide vial (or pre-filled pen), bacteriostatic water (if reconstituting a vial), alcohol swabs, insulin syringe (31-32 gauge, 4-6 mm needle for subcutaneous injection).

  2. 2
    Step 2

    If using a compounded vial: add 2 mL bacteriostatic water slowly down the side of the vial. Swirl gently until dissolved. Never shake. For a 10 mg vial, final concentration is 5 mg/mL. For a 15 mg vial, concentration is 7.5 mg/mL.

  3. 3
    Draw your dose

    At 5 mg/mL concentration: 50 units on the syringe equals 2.5 mg. 100 units equals 5 mg. At 7.5 mg/mL concentration: 100 units equals 7.5 mg. 67 units equals approximately 5 mg. Calculate your dose carefully for each vial concentration.

  4. 4
    Clean the injection site with an alcohol swab

    Choose abdomen (2 inches from the navel), thigh (front or outer), or upper arm. Rotate sites each week.

  5. 5
    Step 5

    Pinch the skin gently and insert the needle at a 90-degree angle. Inject slowly and hold for 5 to 10 seconds before withdrawing.

  6. 6
    Inject once weekly, same day each week

    Many users prefer evening injections to sleep through the 4 to 8 hour nausea window. Timing relative to meals isn't critical, but small, low-fat meals for 24 to 48 hours after injection improve tolerability.

  7. 7
    Titration schedule: start at 2.5 mg for at least 4 weeks

    Increase by 2.5 mg every 4 weeks (or 6 to 8 weeks per the community protocol if GI symptoms persist). Target your lowest effective dose; not everyone needs 15 mg.

  8. 8
    Step 8

    Storage: refrigerate reconstituted vials at 2-8 degrees C (36-46 degrees F). Use within 4 weeks. Brand pens follow the same storage requirements. Pre-filled pens can be stored at room temperature (up to 30 degrees C / 86 degrees F) for up to 21 days per the Zepbound label.

Mixing your own vial? Use the Tirzepatide reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Tirzepatide Stacking Protocols

Works With

Avoid

Semaglutide

Both activate GLP-1 receptors: combining produces additive GLP-1 stimulation with dramatically increased nausea, vomiting, dehydration, and hypoglycemia risk. No additive benefit over tirzepatide monotherapy. When switching from semaglutide to tirzepatide, allow at least one half-life (~7 days) before starting tirzepatide to avoid overlap.

Do not combine
Liraglutide

GLP-1 receptor agonist: overlapping mechanism with tirzepatide's GLP-1 component. Combination increases GI side effects and hypoglycemia risk with no additive weight-loss benefit.

Do not combine
Retatrutide

Triple agonist (GIP/GLP-1/GCG) with fully overlapping GIP and GLP-1 receptor targets. Combining is mechanistically redundant and dramatically increases GI side effects and hypoglycemia risk.

Do not combine
MK-677 (Ibutamoren)

GH secretagogue that significantly stimulates appetite via the ghrelin pathway: directly antagonizes tirzepatide's primary appetite-suppression mechanism. Also promotes insulin resistance, opposing tirzepatide's glycemic benefits.

Do not combine

How much does Tirzepatide cost?

Typical price

$5.67 to $9.00 per mg

Typical $7.50

Middle half of 60 US prices for 10 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, not Mounjaro, Zepbound or any other FDA-approved medicine.

Brand Price
Zepbound brand pens: ~$1,079–$1,086/month list price (without insurance, April 2026). With commercial insurance savings card: as low as $25/fill (max savings $1,300/year). Mounjaro (T2D indication): similar list price. Medicare/Medicaid ineligible for savings cards per federal law.
Generic / Research
No generic available. Tirzepatide is under active Eli Lilly patent protection.
Compounded
Compounded tirzepatide largely unavailable since March 19, 2025. FDA ended enforcement discretion for 503B outsourcing facilities (March 19, 2025) and 503A pharmacies (Feb 18, 2025). Federal court upheld FDA decision May 2025. Historical compounded price: $150–$400/month. Not on the FDA drug shortage list (Federal Register 2026-08552, May 1, 2026; FDA shortage data, October 2026). LillyDirect self-pay (brand Zepbound vials or KwikPen, NOT compounded; October 2026): $299/month (2.5 mg), $399 (5 mg), $449 (7.5–15 mg) with a refill within 45 days, otherwise $499–$699.

Pricing updated 2026-10-17

Tirzepatide Side Effects

Tirzepatide carries a black box warning for thyroid C-cell tumors. In rodent studies, it caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this translates to humans is unknown, and no confirmed human cases have been attributed to tirzepatide. The drug is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Gastrointestinal side effects are the most common reason people struggle with tirzepatide. In the SURMOUNT and SURPASS trials, nausea affected 12 to 29% of patients (dose-dependent, worst at higher weight-management doses). Diarrhea occurred in 13 to 17%. Vomiting hit 8 to 10%. Constipation affected 7 to 11%. Most of these effects are mild-to-moderate and improve with slow dose titration; the community-preferred 6 to 8 week steps between dose increases reduce GI burden compared to the FDA label's 4-week minimum.

Decreased appetite (9 to 11%) is technically a side effect, though most users consider it the primary benefit. Sulfur burps are a community-reported nuisance during escalation phases that clinical trials don't track well.

Hair thinning (telogen effluvium) affects roughly 4 to 5% of users versus about 1% on placebo. This isn't a direct drug effect. Rapid weight loss and caloric restriction trigger a hair growth cycle shift that typically starts 2 to 3 months in and resolves on its own by month 9 to 12.

Injection-site reactions occur in 4 to 7% of patients. Rotating injection sites between the abdomen, thigh, and upper arm helps. Let the vial reach room temperature for 15 to 20 minutes before injecting.

Pancreatitis is rare but serious. Severe, persistent abdominal pain warrants immediate medical evaluation. Serum lipase testing should happen only when pancreatitis is clinically suspected; routine screening isn't indicated.

Gallbladder disease and hypersensitivity reactions are uncommon but documented in clinical trials. Stop tirzepatide and seek medical care if you develop signs of anaphylaxis, severe abdominal pain, or jaundice.

Low blood pressure is a smaller but real signal. On the Zepbound label, hypotension hit 1.6% on tirzepatide vs 0.1% on placebo in the pooled weight-loss trials. It ran higher in people also taking blood pressure medication (2.2% vs 1.2% without it) and showed up alongside gastrointestinal side effects and dehydration. A 2026 meta-analysis pooled 32 randomized trials of tirzepatide and semaglutide (47,332 people)[9]. Tirzepatide carried 2.45 times the risk of hypotension-related events (95% CI 1.35 to 4.45). The risk rose at higher doses, and semaglutide showed no significant change. Lightheadedness when you stand up is worth a blood pressure check, especially if you take antihypertensives.

Muscle loss is a legitimate concern. Approximately 25% of weight lost on tirzepatide is lean mass (SURMOUNT-1 body composition data). Resistance training 3 to 4 times per week and protein intake of at least 1.2 g/kg body weight per day are the primary countermeasures.

Pregnancy and breastfeeding: tirzepatide is contraindicated. Stop treatment at least 2 months before planned conception due to the 5-day half-life and limited reproductive safety data.

Common Issues & Solutions

Nausea after injection: Take injection in the evening to sleep through peak plasma levels (4-8 hr post-dose). Eat small, low-fat meals for 24-48 hr post-injection. If nausea is severe, hold at current dose for 6-8 weeks before attempting escalation. Ginger tea, B6, or ondansetron (if prescribed) are community-used adjuncts.

Weight-loss plateau: First verify protein intake (≥1.2 g/kg), caloric balance, and that food habits have not crept back. A 4-8 week plateau at a stable dose is normal during recomposition. If confirmed plateau after 8+ weeks, escalate dose by one 2.5 mg step. Adding resistance training accelerates fat loss during plateaus.

Constipation: Daily fiber target 25-35g. Add psyllium husk (1-2 tbsp/day) or polyethylene glycol (MiraLAX): most effective OTC option in this context. Minimum 2L water daily. Physical activity stimulates GI motility. Do not use stimulant laxatives long-term.

Hair thinning (telogen effluvium): Typically starts 2-3 months into significant weight loss, peaks at 3-6 months, self-resolves by month 9-12. Not a direct tirzepatide effect: consequence of caloric restriction and physiological stress. Ensure adequate protein, iron, zinc, and biotin intake.

Injection site reactions: Rotate sites systematically between abdomen, thigh, and upper arm. Allow peptide to warm to room temperature (15-20 min out of fridge) before injecting. Use 4-6 mm, 31-32 gauge needle for SC injection. Avoid areas of lipohypertrophy. Lumps/bruising are normal but avoid the same site for 1-2 weeks.

Ask AI about this page

Ask AI for a second opinion on Tirzepatide dosing and side effects

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • History of pancreatitis or active pancreatitis
  • Pregnancy or planning to become pregnant (stop at least 2 months before conception)
  • Breastfeeding
  • Known hypersensitivity to tirzepatide or any excipients
  • Severe gastrointestinal disease (e.g., gastroparesis)

Drug Interactions

  • Insulin and sulfonylureas: increased hypoglycemia risk; dose reduction often needed
  • Oral contraceptives: reduced efficacy due to delayed gastric emptying; use barrier method for 4 weeks after initiation and each dose escalation
  • Oral medications with narrow therapeutic index (e.g., warfarin): monitor closely due to delayed gastric emptying
  • Other GLP-1 receptor agonists (semaglutide, liraglutide): do not combine; overlapping mechanism
  • Oral medications requiring threshold concentrations: absorption timing may shift; monitor efficacy
  • GLP-1 receptor agonist: overlapping mechanism with tirzepatide's GLP-1 component. Combination increases GI side effects and hypoglycemia risk with no additive weight-loss benefit.
  • Triple agonist (GIP/GLP-1/GCG) with fully overlapping GIP and GLP-1 receptor targets. Combining is mechanistically redundant and dramatically increases GI side effects and hypoglycemia risk.

Product Quality

Recommended Monitoring

TestWhenTarget
HbA1c and fasting plasma glucoseBaseline, then every 3 months (T2D) or every 6 months (obesity without diabetes)HbA1c <7.0% (T2D); fasting glucose 70-100 mg/dL
Body weight and waist circumferenceMonthly minimum; at every clinical encounterNot listed
Lipid panel (LDL-C, HDL-C, triglycerides, non-HDL-C)Baseline, 3-6 months, then annuallyNot listed
Serum creatinine / eGFRBaseline, then at 3-6 months: especially if significant GI fluid losses during escalationNot listed
TSH (thyroid stimulating hormone)Baseline; repeat if symptoms of thyroid disease develop (neck mass, hoarseness, dysphagia)Not listed
Serum lipaseOnly if severe persistent abdominal pain occurs: NOT a routine screening testNot listed
Resting heart rateAt each clinical encounter or via home monitoringIncrease <20 bpm above personal baseline; refer for cardiology review if exceeding this
Body composition (DEXA or InBody)Optional: baseline and every 6-12 months for users prioritizing lean mass preservationNot listed
HbA1c and fasting plasma glucose

Primary efficacy endpoint for T2D. Monitor for hypoglycemia if on concurrent insulin or sulfonylureas. Target A1c <7.0% for T2D patients per ADA guidelines.

Body weight and waist circumference

Primary efficacy marker for obesity indication. Less than 5% weight loss at 16 weeks on highest tolerated dose is a signal to reassess treatment.

Lipid panel (LDL-C, HDL-C, triglycerides, non-HDL-C)

Tirzepatide significantly improves lipid profile alongside weight loss. Baseline establishes comparison point.

Serum creatinine / eGFR

GI side effects (vomiting, diarrhea) can cause dehydration and AKI. Monitor renal function during dose escalation phases.

TSH (thyroid stimulating hormone)

Black box warning for thyroid C-cell tumors (rodent data; human relevance unknown). Contraindicated in personal/family history of MTC or MEN2. Baseline TSH provides clinical reference point.

Serum lipase

To rule out acute pancreatitis, which is rare but serious. GI side effects of tirzepatide can mimic pancreatitis symptomatically.

Resting heart rate

GLP-1 agonists increase resting heart rate (mean +1-2 bpm with tirzepatide, less than semaglutide per SURMOUNT-5). Clinically relevant for patients with arrhythmia history.

Body composition (DEXA or InBody)

SURMOUNT-1 data: ~25% of weight loss is lean mass. Provides objective data on resistance training protocol efficacy. Not required per FDA label but recommended by obesity medicine specialists.

Tirzepatide Before and After

Weeks 1-4

Starting dose 2.5mg weekly. Appetite suppression begins within days. Nausea is most common but usually mild. Minimal weight loss expected: this is a tolerability phase.

Weeks 5-8

Dose escalated to 5mg. Noticeable hunger reduction. Early weight loss of 2-4% body weight. GI side effects typically improving.

Weeks 9-12

Dose escalated to 7.5mg. Steady weight loss continues. Blood sugar improvements measurable on labs.

Weeks 13-16

Dose escalated to 10mg. Significant appetite changes. Cumulative weight loss approaching 8-10%.

Weeks 17-20

Dose escalated to 12.5mg, then 15mg if tolerated. Maximum efficacy phase begins. SURMOUNT-1 showed 20.9% weight loss at 72 weeks on 15mg.

Weeks 21-72

Maintenance at maximum tolerated dose (5-15mg). Weight loss continues to plateau around 20-25%. Cardiovascular and metabolic markers significantly improved.

What to Expect

Weeks 1 to 4, Tolerability Phase (2.5 mg): Clinical trials showed negligible weight change at 2.5 mg because this dose exists purely for GI tolerance. Community experience tells a different story on appetite, though. Most users on r/Zepbound report food noise diminishing within days of their first injection. Some drop 2 to 5 lbs in the first week, mainly water weight and reduced GI volume. Side effects at this dose are mild for most: light nausea, fatigue, decreased appetite. Don't evaluate whether tirzepatide works based on this phase.

Weeks 5 to 12, Dose Escalation (5 to 7.5 mg): Each 2.5 mg step-up triggers a GI flare that typically lasts 1 to 2 weeks before the body adapts. The community calls 5 mg "the wall" because nausea peaks here for many users. Cumulative weight loss of 3 to 6% is expected by week 12. Constipation becomes a persistent companion; daily fiber and adequate water are non-negotiable. Sulfur burps and fatigue during the first week at each new dose are commonly reported. Visible weight loss starts validating the discomfort.

Weeks 13 to 20, Reaching Maintenance Dose (7.5 to 12.5 mg): Most users find their sweet spot somewhere in this range. Food noise goes largely silent. Energy improves. Community posts shift from asking "does this work?" to discussing muscle preservation, clothing sizes, and whether to keep escalating. Cumulative weight loss sits at 8 to 14% depending on dose. Lab markers (A1c, blood pressure, triglycerides) show measurable improvement. GI side effects decrease substantially at a stable dose, but constipation sticks around. Hair thinning may start for some.

Weeks 21 to 52, Maximum Efficacy Phase: Weight loss continues accumulating toward the 20 to 22% range at maximum tolerated dose. SURMOUNT-1 data showed roughly 20 to 22% reduction by week 52 at 15 mg. Side effects are minimal once you've been at a stable dose for several weeks. Sleep apnea resolution is commonly reported. Reduced alcohol cravings show up frequently in community posts. Telogen effluvium starts resolving. Some people report cold intolerance as they lose significant weight.

Week 72 and beyond, Long-term Maintenance: Weight loss plateaus near 20.9% at maximum dose, the SURMOUNT-1 figure counting everyone randomized. The SURMOUNT-1 three-year follow-up [6] showed 94% type 2 diabetes prevention in the prediabetes group versus 40% with lifestyle changes. Community discussion centers on one question: "can I ever stop?" Consensus points to indefinite treatment for most, similar to blood pressure or cholesterol medications. Some experiment with gradual dose reductions. Cost and insurance remain the dominant long-term concerns. Weight regain within weeks of stopping or reducing dose is the consistent theme across both trial data and community reports.

Detailed Timeline: Science vs Community

Weeks 1–4
Science

Minimal weight loss. Purpose is GI tolerance establishment. Mean weight change at 4 weeks is negligible in clinical trials.

Community

Most users notice appetite suppression within days of first injection even at 2.5 mg. Some lose 2-5 lbs in week 1, often water weight and reduced GI volume. Community excitement is high; many are surprised how quickly food noise diminishes.

Weeks 5–12
Science

Each 2.5 mg step-up produces a transient GI side effect flare for 1-2 weeks before adaptation. Cumulative weight loss 3-6% by week 12 expected.

Community

GI side effects peak at the 5 mg step for many users. Community calls this "the 5 mg wall." Most push through with slow titration. Visible weight loss validating the side effects. Body composition changes begin.

Weeks 13–20
Science

Cumulative weight loss 8-14% by week 20 depending on dose. A1c, blood pressure, and triglycerides show significant improvement.

Community

Many users find their "sweet spot" dose (often 7.5-12.5 mg). Food noise largely silent. Energy improving. Posts shift from "does it work?" to muscle preservation, clothing sizes, and dose decisions. SURMOUNT-5 results widely discussed: community validates head-to-head superiority over semaglutide.

Weeks 21–52
Science

Weight loss continues to accumulate and plateau. SURMOUNT-1: ~20-22% loss by week 52 at 15mg. HbA1c, blood pressure, and lipids substantially improved. Cardiovascular risk factors declining.

Community

Sustained weight loss. Community focus shifts to maintenance, muscle preservation, and long-term planning. Sleep apnea resolution commonly reported. Alcohol cravings reduced. "I forgot what hunger feels like" is a common theme.

Week 72+
Science

Weight loss plateaus near 20.9% at maximum dose (SURMOUNT-1, counting everyone randomized). SURMOUNT-1 3-year follow-up: 94% T2D prevention in prediabetes group (vs 40% lifestyle alone). Weight regain of ~two-thirds within 12 months of discontinuation.

Community

Weight loss has stabilized. Many debating "Can I ever come off?" Community consensus: likely a lifelong treatment for most, similar to antihypertensives or statins. Some experiment with dose reductions. Cost and insurance are dominant long-term concerns.

Pharmacokinetics

Half-Life
120h
Bioavailability
SC: ~80%
Tmax
8-72 hours
Data Confidence
high

Source: Mounjaro FDA Label, Section 12.3; confirmed by PopPK analysis (t½ ~117h)

Pharmacokinetics: Active Dose Over Time

t½ = ~5 days

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
39
Molecular Weight
4,813.45 Da
Sequence
YAEGTFTSDYSIALDKIAQKAFVQWLIAGGPSSGAPPPS
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons

Who Should Consider Tirzepatide

  • Adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
  • Type 2 diabetics needing superior glycemic control
  • Patients who plateaued on semaglutide or liraglutide
  • Those seeking the most potent FDA-approved weight-loss injectable
  • Adults with obesity-related cardiovascular risk factors
  • Adults with moderate-to-severe obstructive sleep apnea and obesity (FDA-approved December 2024)

Related Peptides

What Changed for Tirzepatide

  1. Safety

    Mounjaro's existing diabetic retinopathy warning (5.7) was revised on Aug 27, 2026, per the FDA label; no new retinopathy warning was added.

    Source: Mounjaro (tirzepatide) prescribing information, SPL version 40, effective 2026-08-27 (openFDA label record) (opens in a new tab) · Saved copy

  2. Regulatory

    FDA added a major adverse cardiovascular event risk indication in type 2 diabetes to Mounjaro (S-044, S-045) on Aug 27, 2026, per the updated FDA label.

    What this does not mean: SURPASS-CVOT showed noninferiority to dulaglutide, not superiority. Zepbound did not gain this indication.

    Source: Mounjaro (tirzepatide) prescribing information (openFDA label record, SPL version 40, effective Aug 27, 2026) (opens in a new tab) · Saved copy

  3. Safety

    Zepbound supplement S-041 revised the existing diabetic retinopathy warning (5.8) on Aug 26, 2026, per the updated label; no cardiovascular indication.

    Source: Zepbound (tirzepatide) prescribing information (openFDA label record, SPL version 40, effective Aug 28, 2026) (opens in a new tab) · Saved copy

  4. Safety

    A meta-analysis of 32 tirzepatide and semaglutide trials found more hypotension-related events on tirzepatide (RR 2.45), published Aug 15, 2026, per Endocrine.

    Before: No hypotension text. After: Hypotension paragraph: Zepbound label 1.6% vs 0.1% on placebo; meta-analysis RR 2.45 (95% CI 1.35 to 4.45), higher at higher doses.

    What this does not mean: Hypotension stays uncommon: the Zepbound label reports 1.6% vs 0.1% on placebo, higher with blood pressure drugs or GI fluid loss.

    Source: Endocrine 2026, Effect of tirzepatide and semaglutide on blood pressure: systematic review and meta-analysis (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  5. Regulatory

    FDA extended comments on its 503B proposal for semaglutide, tirzepatide and liraglutide to Jul 30, 2026, per Federal Register 2026-12937.

    What this does not mean: An extension of the comment period only. FDA has not made a final decision on the proposal.

    Also covers: Semaglutide, Liraglutide

    Source: Federal Register 2026-12937 (91 FR 38719, Jun 26, 2026) (opens in a new tab) · Saved copy

  6. Regulatory

    FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list on May 1, 2026, per Federal Register 2026-08552.

    What this does not mean: A proposal, not a final decision. It does not touch the FDA-approved brand products; it concerns bulk substances for outsourcing facilities.

    Also covers: Semaglutide, Liraglutide

    Source: Federal Register 2026-08552 (91 FR 23431, May 1, 2026) (opens in a new tab) · Saved copy

  7. Safety

    Zepbound labeling supplement S-042 took the suicidal behavior and ideation warning off the label on Feb 25, 2026, per the updated FDA label.

    Source: Zepbound (tirzepatide) prescribing information (openFDA label record, SPL version 40; Recent Major Changes lists the warning as removed 02/2026) (opens in a new tab) · Saved copy

  8. Safety

    FDA asked makers to take the suicidal behavior and ideation warning off Saxenda, Wegovy and Zepbound labels on Jan 13, 2026, per an FDA safety communication.

    What this does not mean: FDA found no increased risk of suicidal ideation or behavior in its review. The diabetes-only GLP-1 labels never carried this warning.

    Also covers: Liraglutide, Semaglutide

    Source: FDA Drug Safety Communication, Jan 13, 2026: FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 9, 202622 Citations

References

  1. [1]SURMOUNT-1: SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity (opens in a new tab)(n=2,539)PubMed (opens in a new tab)PubMed
  2. [2]SURMOUNT-5: SURMOUNT-5: Tirzepatide vs Semaglutide for Obesity (NEJM 2025) (opens in a new tab)(n=751)PubMed (opens in a new tab)PubMed
  3. [3]SURPASS diabetes: SURPASS-1: Tirzepatide vs Placebo in Type 2 Diabetes (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]SURPASS diabetes: SURPASS-2: Tirzepatide vs Semaglutide in Type 2 Diabetes (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]SURMOUNT-OSA: SURMOUNT-OSA: Tirzepatide for Obstructive Sleep Apnea and Obesity (NEJM 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]SURMOUNT-1: Tirzepatide for Prevention of T2D in Obesity: SURMOUNT-1 3-Year Follow-Up (2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]SUMMIT: Tirzepatide for Heart Failure with Preserved Ejection Fraction (NEJM 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  8. [8]SYNERGY-NASH: SYNERGY-NASH: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (NEJM 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  9. [9]Effect of tirzepatide and semaglutide on blood pressure: systematic review and meta-analysis of 32 RCTs (Endocrine 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed

Additional References

Related Resources

Related Tools

Further Reading

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C
After Reconstitution
Refrigerate at 2-8°C, use within 4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

Start at 2.5 mg weekly for 4 weeks, then titrate to 5 mg. From there, increases of 2.5 mg every 4 weeks up to a maximum of 15 mg weekly. SURMOUNT-1 used the 5/10/15 mg doses. Most weight loss benefit hits a ceiling around 10-15 mg for most people.

Nausea (17-25%, dose-dependent), diarrhea (13-17%), and vomiting (8-10%) were the most common in SURMOUNT-1. These peak during dose escalation and usually resolve within 4-8 weeks at a stable dose. Injection site reactions occur in about 3-7%. Pancreatitis, gallbladder events, and gastroparesis are rare but documented.

Tirzepatide targets both GIP and GLP-1 receptors; semaglutide targets GLP-1 only. SURMOUNT-1 showed 20.9% mean weight loss at 72 weeks on 15 mg tirzepatide. Semaglutide's STEP 1 showed 14.9% at 68 weeks on 2.4 mg. SURMOUNT-5 (PMID 40353578, n=751) ran a direct comparison: tirzepatide 15 mg achieved 20.2% weight loss versus 13.7% for semaglutide 2.4 mg at 72 weeks.

Yes. Mounjaro is FDA-approved for type 2 diabetes (2022) and Zepbound for chronic weight management (2023). Both are manufactured by Eli Lilly. The weight management approval covers adults with BMI 30+ or BMI 27+ with a weight-related comorbidity.

Most users notice appetite reduction within the first 1-2 weeks. Measurable weight loss typically appears by week 4-8. The SURMOUNT-1 trial showed the steepest weight loss curve between weeks 12-36, with results plateauing around week 60-72.